March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Rapid Crosslinking of Lacritin by Tissue Transglutaminase - a Major Form of Lacritin in Human Tears, and Lacrimal and Salivary Glands
Author Affiliations & Notes
  • Francisco Velez, V
    Cell Biology, University of Virginia, Charlottesville, Virginia
  • Robert L. McKown
    Integrated Science & Technology,
    James Madison University, Harrisonburg, Virginia
  • Ronald W. Raab
    2Integrated Science & Technology,
    James Madison University, Harrisonburg, Virginia
  • D. S. Ryan
    U.S. Army Warfighter Refractive Surgery Research Center at Fort Belvoir, Fort Belvoir, Virginia
  • Gordon W. Laurie
    Cell Biology, University of Virginia, Charlottesville, Virginia
  • Footnotes
    Commercial Relationships  Francisco Velez, V, None; Robert L. McKown, Eye Rx (F), UVa Patent Foundation (P); Ronald W. Raab, None; D. S. Ryan, None; Gordon W. Laurie, Eye Rx (F), UVa Patent Foundation (P)
  • Footnotes
    Support  EYO18222, EYO13143 to (GWL)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4232. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francisco Velez, V, Robert L. McKown, Ronald W. Raab, D. S. Ryan, Gordon W. Laurie; Rapid Crosslinking of Lacritin by Tissue Transglutaminase - a Major Form of Lacritin in Human Tears, and Lacrimal and Salivary Glands. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4232.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Lacritin is a small glycoprotein largely secreted by lacrimal acinar cells to be released into tears where it promotes basal tear secretion, selective epithelial cell proliferation, and plays a cytoprotective role. Several studies suggest that 23 kDa (monomeric) lacritin may be selectively downregulated in dry eye. While characterizing a new generation of anti-lacritin N- vs C-domain-specific antibodies (including mab 1F5-C9-F4) with N- and C-truncation mutants, immunoreactive 75 to 83kDa material was noted in human tear, and lacrimal gland and salivary gland blots. Here, we report that lacritin serves as a substrate for tissue transglutaminase (TGM2) as a possible mechanism for diminishing levels of monomeric lacritin.

Methods: : 1F5-C9-F4 N-terminal specific anti-lacritin monoclonal antibody was generated and tested in blots against lacritin and lacritin truncation mutants, or of human tears or human lacrimal and salivary gland lysates. New N- and C-terminal polyclonal antibodies were also tested. In cross-linking studies, 3 µM lacritin was incubated in HEPES (37°C) containing 10 mM Ca2+ and 1.5 µM TGM2 with or without 30 µM of competitive inhibitor. The reaction was terminated by adding 50 mM EDTA, and blotted with 1F5-C9-F4.

Results: : Greater than 90% of lacrimal and salivary gland lacritin appear to be cross-linked in samples of the individuals tested. Monomeric lacritin is modified by TGM2 within 1 min and converted into 73 to 250 kDa multimers within 40 min. The N- and C-terminal halves are both subject to cross-linking activity. Candidate amine acceptors include Gln14, Gln42, Gln50, or Gln60 in the N-terminal half and Gln96 or Gln106 in the C-terminus.

Conclusions: : Human tear, lacrimal and salivary gland lacritin is subject to multimerization by TGM2, a component of human tears. Bioactivity could thereby be affected.

Keywords: cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×